You are here

Rallybio

Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech

Pharma Voice

Tue, 11/5/24 - 10:02 am

clinical trials

Rallybio reins in preclinical R&D, while Monopar pivots to radiopharma to eke out cash

Fierce Biotech

Thu, 05/9/24 - 11:32 am

Monopar Therapeutics

radiopharmaceuticals

J&J, Rallybio partner on drug development for rare fetal condition

BioPharma Dive

Wed, 04/10/24 - 06:01 pm

drug development

Rallybio, AbCellera partner to develop therapeutics for rare diseases

Pharmaceutical Business Review

Fri, 12/2/22 - 10:54 am

As Sanofi prunes pipeline, ex-Alexion crew at Rallybio picks up anemia drug

Endpoints

Tue, 05/10/22 - 10:56 am

Three Biopharma Companies Made Public Debut on Nasdaq Exchange

BioSpace

Thu, 07/29/21 - 10:59 pm

Rallybio hits high gear as it targets $100M IPO to fund treatments for rare fetal bleeding disorder

Fierce Biotech

Tue, 07/6/21 - 10:51 am

Martin Mackay’s rare disease startup gets $145 million as it enters the clinic

Endpoints

Tue, 05/19/20 - 10:42 am